Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2008
Date:8/13/2008

Conference Call & Webcast Today at 2:00 p.m. CET

AMSTERDAM, August 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2008.

Highlights

- Positive results of pivotal trial for Glybera(R) (AMT-011)

for Hyperlipoproteinemia type I

- European patent for treatment of Non-Alcoholic Steatotic

Hepatitis

- License for treatment of Duchenne Muscular Dystrophy from La

Sapienza University, Rome, Italy

- License for prevention of immune response against treatment of

Hemophilia B from 'TIGET", San Raffaele Telethon Gene Therapy Institute,

Milan, Italy

- Collaboration with St. Jude Children's Research Hospital,

Memphis, Tennessee, USA, including license for treatment of Hemophilia B

- GMP manufacturing development: License for raising yields of

production platform from NIH, Bethesda, USA

- Key financial figures in line with guidance

- Cash & cash equivalents of EUR 43.1 million at June 30, 2008

- Independent supervisory board with three new members bringing

extensive knowledge and experience.

Results comparison

AMT's key financial figures are in line with the guidance that the company has given for 2008. The operating loss increased to EUR 9.1 million for the six months ended June 30, 2008, from EUR 7.2 million for the same period in 2007. This difference is primarily due to the increase of research & development costs to EUR 5.8 million from EUR 3.8 million in the same period of 2007. This increase is particularly related to the development work on the company's lead product Glybera(R) (AMT-011) and increased staffing for this and other programs. General and administrative costs decreased slightly to EUR 3.3 million from EUR 3.5 million for the same period in 2007 due to lower share-based payments.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Part of Next Biotech Index
2. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
3. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
5. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
9. Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
10. New Turbomolecular Pumping System From Varian, Inc. Delivers Portable, Dry, Ultra-high Vacuum.
11. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Richmond, VA (PRWEB) November 21, 2014 ... businessman who understood the need to surround himself with ... visionary, CEO and entrepreneur, his friends often marveled at ... how he lived his life and -- even with ... cure for the Alzheimer’s disease that would ultimately take ...
(Date:11/22/2014)... 21, 2014 On November 17th Chicago ... 2014 Emerging Medical Technologies Summit in San Francisco to ... Widely regarded among Silicon Valley investors and technology elites ... the win also positions Briteseed to move on ... in 2015 and compete with other elite innovation finalists ...
(Date:11/22/2014)... , November 21, 2014   ... als Chief Commercial Officer zu KLOX    ... Unternehmensentwicklung und Chief Financial Officer bestellt    ... der Vermarktung seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu ... bzw. das "Unternehmen") ist sehr erfreut, die folgenden personellen ...
(Date:11/21/2014)... Offering a complete line of laboratory balances, ... . The Sartorius Entris Balance is the perfect laboratory ... easy-to-maintain balance entry level balance. , The Entris was ... help customer’s bridge the gap between a basic balance ... durable. Sartorius is the second biggest balance manufacturer in ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2
... The Netherlands, April 28 , ... Brachytherapy Represents the,Next Generation in DICOM-Compatible, ... a knowledge-based leader in radiation oncology, ... a comprehensive,volume-based treatment planning system to ...
... Simcere,Pharmaceutical Group (NYSE: SCR ), a leading ... of the patented,anti-cancer biotech product Endu in China, ... of its existing shareholders, New Good Management,Limited, a ... including certain senior management of Simcere Pharmaceutical,has entered ...
... on a Non-Exclusive Basis, Proprietary MicroRNAs ... Agreement, Rosetta Genomics has Access to a Full Range ... MicroRNA Applications Based on These MicroRNAs, REHOVOT, Israel ... (Nasdaq: ROSG ), a leading,developer of microRNA-based diagnostics ...
Cached Biology Technology:Nucletron Announces Oncentra(R) Brachy* Treatment Planning Solution for Multimodality Environment 2Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 2Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 3Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 2Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 3Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
(Date:11/2/2014)... support of a bold quest to rid the world ... today announced an award of US$156 million to PATH ... building new vaccines that will interrupt the cycle of ... zero" agenda. Such vaccines would ensure that parasite reintroduction ... "immunological bed net." , This approach to developing ...
(Date:11/2/2014)... and bump into a biologist . . . , While ... sketch, researchers have taken this premise and applied it to ... in the rising oceans of genomic data. , In this ... studies are publishing at a dizzying rate. The challenge is ... the noise (and there is no shortage of noise). , ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... Institute of Allergy and Infectious Diseases (NIAID), part of ... powerful inhibitor of anthrax toxin that worked well in ... the design of anthrax antitoxin is an important advance, ... anthrax treatment, but also because this technique could be ...
... in North America, two types of invasive vines are ... butterfly populations and bird habitats. , The vines are ... control to stem the growth of and their steady ... and Canada, Cornell University is teaming up with the ...
... images of other monkeys glancing one way or the ... high-ranking monkeys, Duke University Medical Center neurobiologists have discovered. ... low-status monkeys; while low-status monkeys assiduously follow the gaze ... than a confirmation of what most people believe about ...
Cached Biology News:Scientists design potent anthrax toxin inhibitor 2Scientists design potent anthrax toxin inhibitor 3CU, USDA team to curb two invasive, poisonous vines 2CU, USDA team to curb two invasive, poisonous vines 3'Executive' monkeys influenced by other executives, not subordinates 2'Executive' monkeys influenced by other executives, not subordinates 3
... Luminometer has been designed,for the detection ... measurements of glow and flash luminescence ... light remain nearly constant,over a longer ... for very fast reactions,requiring at least ...
... than western blotting. Get results sooner and save ... gel detection. Eliminates the need for a membrane ... All reagents are ready-to-use. No reagents to prepare ... 2 reagents required. Guarantees a simple to perform, ...
... The EZ-Tn5™ Plasmid-Based Deletion Machine is ... vitro transposition system developed by Goryshin and ... generation of nested families of deletions and ... cloned in a transposon-containing plasmid vector. Although ...
... This kit is designed to knockout or alter ... less than one week. Red/ET recombination allows the ... precise, specific, and faithful manner. An FRT-flanked kanamycin ... which can be used to replace a gene ...
Biology Products: